Document Detail


Bivalirudin Versus Heparin as an Anticoagulant During Extracorporeal Membrane Oxygenation: A Case-Control Study.
MedLine Citation:
PMID:  23036625     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: Heparin-based anticoagulation for patients undergoing extracorporeal membrane oxygenation has many limitations, including a high risk of heparin-induced thrombocytopenia. However, little experience with other anticoagulants in these patients has been described. The aim of this study was to compare bivalirudin-based anticoagulation with heparin-based protocols in a population of patients treated with venovenous or venoarterial extracorporeal membrane oxygenation. DESIGN: In this case-control study, 10 patients received bivalirudin (cases) and 10 heparin (controls). The target activated partial thromboplastin time (aPTT) was 45 to 60 seconds. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: aPTT variations >20% of the previous value were much more frequent in patients treated with heparin than in patients receiving bivalirudin (52 v 24, p < 0.001). The number of corrections of the anticoagulant dose was higher in the heparin group compared with the bivalirudin group (58 v 51), although it did not reach statistical significance. Bleeding, thromboembolic complications, extracorporeal membrane oxygenation (ECMO) support duration, mortality, and the number of episodes of aPTT >80 seconds were not different between the 2 groups. A further analysis was performed in the bivalirudin group according to the presence of acute renal failure requiring continuous venovenous hemofiltration. The median bivalirudin dose in patients with or without hemofiltration was 0.041 (0.028-0.05) mg/kg/h and 0.028 (0-0.041) mg/kg/h, respectively (p = 0.2). CONCLUSIONS: Bivalirudin-based anticoagulation may represent a new method of anticoagulation for reducing thromboembolic and bleeding complications, which still jeopardize the application of extracorporeal membrane oxygenation. Moreover, bivalirudin is free from the risk of heparin-induced thrombocytopenia. Higher doses of bivalirudin may be needed in patients undergoing hemofiltration.
Authors:
Marina Pieri; Natalia Agracheva; Enrico Bonaveglio; Teresa Greco; Michele De Bonis; Remo Daniel Covello; Alberto Zangrillo; Federico Pappalardo
Related Documents :
7973475 - Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. a multic...
15334435 - Systemic lupus erythematosus in three ethnic groups. xix. natural history of the accrua...
24168465 - Effects of a nurse-based case management compared to usual care among aged patients wit...
16385495 - The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radio...
22530605 - Joint distraction results in clinical and structural improvement of haemophilic ankle a...
16716165 - Endothelin-1 is significantly elevated in plasma of patients with vitiligo treated with...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-1
Journal Detail:
Title:  Journal of cardiothoracic and vascular anesthesia     Volume:  -     ISSN:  1532-8422     ISO Abbreviation:  J. Cardiothorac. Vasc. Anesth.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9110208     Medline TA:  J Cardiothorac Vasc Anesth     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Department of Cardiothoracic and Vascular Anesthesia and Intensive Care, San Raffaele Scientific Institute, Università Vita-Salute, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of Autonomic Reserves in Cardiac Surgery Patients.
Next Document:  Anesthesia for Transfemoral Aortic Valve Replacement in North America and Europe.